- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02261129
Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers
October 9, 2014 updated by: Boehringer Ingelheim
Bioequivalence of the 80 mg Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)
Study to demonstrate the bioequivalence of the telmisartan 80 mg film-coated tablet vs. two tablets of the telmisartan 40 mg conventional tablet
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Healthy Japanese males according to the following criteria:
Based upon a complete medical history, including the physical examination, vital signs (Blood pressure, pulse rate, body temperature), 12-lead ECG, clinical laboratory tests
- 1.1 No findings deviating from normal and of clinical relevance
- 1.2 No evidence of a clinically relevant concomitant disease
- Age ≥20 and ≤35 years
- Body weight≥50kg
- Body Mass Index ≥18.0 and ≤25.0 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate, body temperature, and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity (including allergy to a drug or its excipients)
- Any clinical relevant findings of the laboratory test deviating from normal
- Positive result for either hepatitis B antigen, anti hepatitis C virus antibodies, syphilitic test or human immunodeficiency virus (HIV) test
- History of surgery of gastrointestinal tract (except appendectomy)
- History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts
- History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
- History of serious renal dysfunction
- History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
- History of cerebrovascular disorder
- History of hyperkalemia
- Known hypersensitivity to any component of the telmisartan formulation, or to any other angiotensin II receptor blockers
- Intake of drugs with a long half-life (≥24 hours) within at least one month or less than 10 half-lives of the respective drug before administration of the investigational product
- Use of any drugs within 10 days before administration of the investigational product or during the trial
- Participation in another trial with an investigational drug within four months before administration of the investigational product or during the trial
- Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- Alcohol abuse
- Drug abuse
- Blood donation (100 mL or more) within four weeks before administration of the investigational product
- Excessive physical activities within one week before administration of the investigational product or during the trial
- Intake of alcohol within 2 days prior to administration
- Inability to comply with dietary regimen of study centre
- Inability to refrain from smoking on trial days
- Any other clinical conditions that investigator or sub-investigator judges that the subject is ineligible for study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telmisartan, film-coated tablet
one tablet of telmisartan
|
|
Active Comparator: Telmisartan, conventional tablet
Two tablets of telmisartan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable data point (AUC0-tz)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Maximum measured concentration of the analyte in plasma (Cmax)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with adverse events
Time Frame: up to 72 hours after last drug administration
|
up to 72 hours after last drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Time from dosing to the maximum measured concentration of the analyte in plasma (tmax)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Terminal rate constant of the analyte in plasma (λz)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Terminal half-life of the analyte in plasma (t1/2)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
mean residence time of the analyte in the body after po administration (MRTpo)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
October 9, 2014
First Submitted That Met QC Criteria
October 9, 2014
First Posted (Estimate)
October 10, 2014
Study Record Updates
Last Update Posted (Estimate)
October 10, 2014
Last Update Submitted That Met QC Criteria
October 9, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 502.557
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Telmisartan film-coated tablet
-
Galapagos NVTerminatedSystemic Lupus ErythematosusSpain, Bulgaria, Moldova, Republic of, Poland, Ukraine
-
LG ChemCompleted
-
Boehringer IngelheimCompleted
-
AstraZenecaQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
Novartis PharmaceuticalsCompletedChronic Iron Overload Due to Transfusion-dependant AnemiasItaly, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
-
AstraZenecaParexelCompletedCoronary Artery Disease (CAD)United Kingdom
-
Chong Kun Dang PharmaceuticalCompletedGastrointestinal Stromal Tumors | Chronic Myeloid LeukemiaKorea, Republic of
-
Damanhour UniversityCompleted
-
H. Lundbeck A/SCompletedBioequivalence Study in Healthy SubjectsRussian Federation
-
Qanatpharma Canada LTDCompletedHealthy VolunteerCanada